Biotechnology: Biological Products (No Diagnostic Substances)

Business UpdateJun 1, 2026, 04:01 PM

Cardiff Oncology to Present at Jefferies Global Healthcare Conference

AI Summary

Cardiff Oncology, Inc. announced that its management will present and participate in investor meetings at the Jefferies Global Healthcare Conference from June 2-4, 2026. President and CEO Mani Mohindru, PhD, will host a Fireside Chat on June 4, 2026, from 10:30 - 11:00 AM ET. Interested parties can access the live webcast and replay via the company's website.

Key Highlights

Cardiff Oncology management to present at the Jefferies Global Healthcare Conference.
President and CEO Mani Mohindru, PhD, will deliver a Fireside Chat.
Presentation scheduled for June 4, 2026, from 10:30 - 11:00 AM ET.
Live webcast and replay will be available on the company's website.
Cardiff Oncology is a clinical-stage biotechnology company focused on PLK1 inhibition.
Lead asset, onvansertib, is in a Phase 2 trial for RAS-mutated metastatic colorectal cancer.

View SEC Filing

CRDF

Biotechnology: Biological Products (No Diagnostic Substances)

Cardiff Oncology, Inc.

Price Impact